Isomorphic Labs applies AI and computational biology to drug discovery and development.
| date | round | amount | valuation | investors |
|---|---|---|---|---|
| May 2026 | Primary | $2.1B | not disclosed | Thrive Capital |
Isomorphic Labs is extending AlphaFold into full drug discovery pipeline — biochemistry, compound design, and virtual cell simulation — with major milestones expected soon and a 10-year path to whole-cell modeling.